Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GLP-1 mimetics and cognition
Habib Yaribeygi, Ali Rashidy‐Pour, Stephen L. Atkin, et al.
Life Sciences (2020) Vol. 264, pp. 118645-118645
Closed Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial
Mette Kruse Klausen, Mathias E. Jensen, Marco Møller, et al.
JCI Insight (2022) Vol. 7, Iss. 19
Open Access | Times Cited: 97
Type 2 diabetes mellitus-associated cognitive dysfunction: Advances in potential mechanisms and therapies
Ailin Luo, Zheng Xie, Yue Wang, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 137, pp. 104642-104642
Closed Access | Times Cited: 84
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Joseph Nowell, Eleanor G Blunt, Dhruv Gupta, et al.
Ageing Research Reviews (2023) Vol. 89, pp. 101979-101979
Open Access | Times Cited: 82
The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome
Krzysztof Bednarz, Karolina Kowalczyk, Marlena Cwynar, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4334-4334
Open Access | Times Cited: 79
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: SOUL , a randomized trial, design and baseline characteristics
Darren K. McGuire, Rodica Pop‐Busui, John Deanfield, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 7, pp. 1932-1941
Open Access | Times Cited: 74
Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway
Zhaojun Wang, Xinru Li, Shi-Fan Chai, et al.
Neuropharmacology (2023) Vol. 240, pp. 109716-109716
Closed Access | Times Cited: 46
Immunotherapies for Neurodegenerative Diseases
Ibrahim Mortada, Raymond Farah, Sanaa Nabha, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 78
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Haiyang Du, Xiaoyu Meng, Yao Yu, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 51
Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists
Puja Ghosh, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Theranostics (2023) Vol. 13, Iss. 14, pp. 4872-4884
Open Access | Times Cited: 25
Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach
Davide Arillotta, Giuseppe Floresta, Guy Pelletier, et al.
Brain Sciences (2024) Vol. 14, Iss. 6, pp. 617-617
Open Access | Times Cited: 15
Anti-inflammatory benefits of semaglutide: State of the art
Habib Yaribeygi, Mina Maleki, Tannaz Jamialahmadi, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100340-100340
Open Access | Times Cited: 13
Sympathetic nerve-enteroendocrine L cell communication modulates GLP-1 release, brain glucose utilization, and cognitive function
Wenran Ren, Jianhui Chen, Wenjing Wang, et al.
Neuron (2024) Vol. 112, Iss. 6, pp. 972-990.e8
Open Access | Times Cited: 10
IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
Nicolaus Bruns, Elizabeth H. Tressler, Leandro F. Vendruscolo, et al.
Pharmacological Research (2024) Vol. 207, pp. 107312-107312
Open Access | Times Cited: 10
Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer’s Disease: A Systematic Review
Yulin Liang, Vincent Doré, Christopher C. Rowe, et al.
Journal of Alzheimer s Disease Reports (2024) Vol. 8, Iss. 1, pp. 777-789
Open Access | Times Cited: 9
The role of the intestinal microbiome in cognitive decline in patients with kidney disease
Carsten A. Wagner, Isabelle Frey‐Wagner, Alberto Ortíz, et al.
Nephrology Dialysis Transplantation (2025) Vol. 40, Iss. Supplement_2, pp. ii4-ii17
Open Access | Times Cited: 1
GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
Shahla Rezaei, Reza Tabrizi, Peyman Nowrouzi‐Sohrabi, et al.
Canadian Journal of Gastroenterology and Hepatology (2021) Vol. 2021, pp. 1-11
Open Access | Times Cited: 42
Glucagon-like Peptide 1 Receptor Activation Inhibits Microglial Pyroptosis via Promoting Mitophagy to Alleviate Depression-like Behaviors in Diabetic Mice
Fan Yang, Xin‐shang Wang, Jingyu Qi, et al.
Nutrients (2022) Vol. 15, Iss. 1, pp. 38-38
Open Access | Times Cited: 28
Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial
Alessandra Dei, M. M. Micheli, Raffaella Aldigeri, et al.
Journal of Endocrinological Investigation (2024) Vol. 47, Iss. 9, pp. 2339-2349
Open Access | Times Cited: 8
Relationship Between Diabetes Mellitus and Periodontal/Peri-Implant Disease: A Contemporaneous Review
Shabnam Enteghad, Farinaz Shirban, Mohammad Hossein Nikbakht, et al.
International Dental Journal (2024) Vol. 74, Iss. 3, pp. 426-445
Open Access | Times Cited: 7
Therapeutic effects of anti-diabetic drugs on traumatic brain injury
Seyed Mehrad Razavi, Zahra Najafi Arab, Amirhossein Niknejad, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 2, pp. 102949-102949
Closed Access | Times Cited: 6
Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimer’s Disease and Type 2 Diabetes
María José Carranza-Naval, Ángel del Marco, Carmen Hierro‐Bujalance, et al.
Frontiers in Aging Neuroscience (2021) Vol. 13
Open Access | Times Cited: 32
The glucagon‐like peptide‐1 system is modulated by acute and chronic alcohol exposure: Findings from human laboratory experiments and a post‐mortem brain study
Mehdi Farokhnia, Brittney D. Browning, Madeline E. Crozier, et al.
Addiction Biology (2022) Vol. 27, Iss. 5
Closed Access | Times Cited: 19
Glp-1 Mimetics and Autophagy in Diabetic Milieu: State-of-the-Art
Habib Yaribeygi, Mina Maleki, Raul D. Santos, et al.
Current Diabetes Reviews (2024) Vol. 20, Iss. 10
Closed Access | Times Cited: 4
NLRP3 inflammasomes pathway: a key target for Metformin
Yasamin Hosseini, Amirhossein Niknejad, Ayeh Sabbagh Kashani, et al.
Inflammopharmacology (2025)
Closed Access
Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study
Xiang Lin, Ying Peng
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2741-2741
Open Access
Page 1 - Next Page

Scroll to top